Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis.
endoscopy
inflammatory bowel disease
infliximab
model-informed precision dosing
monoclonal antibody
population pharmacokinetics-pharmacodynamics
simulations
therapeutic drug monitoring
ulcerative colitis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
06 Oct 2021
06 Oct 2021
Historique:
received:
27
08
2021
revised:
24
09
2021
accepted:
27
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Model-informed precision dosing (MIPD) may be a solution to therapeutic failure of infliximab for patients with ulcerative colitis (UC), as underexposure could be avoided, and the probability of endoscopic improvement (pEI; Mayo endoscopic subscore ≤ 1) could be optimized. To investigate in silico whether this claim has merit, four induction dosing regimens were simulated: 5 mg/kg (label dosing), 10 mg/kg, covariate-based MIPD (fat-free mass, corticosteroid use, and presence of extensive colitis at baseline), and concentration-based MIPD (based on the trough concentration at day 14). Covariate- and concentration-based MIPD were chosen to target the same median area under the infliximab concentration-time curve up to endoscopy at day 84 (AUC
Identifiants
pubmed: 34683916
pii: pharmaceutics13101623
doi: 10.3390/pharmaceutics13101623
pmc: PMC8537637
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : T.B. received a TBM grant (grant number T003117N)
Organisme : Fonds Wetenschappelijk Onderzoek
ID : P.D. received a TBM grant (grant number T003716N)
Organisme : Fonds Wetenschappelijk Onderzoek
ID : M.F. is a Senior Clinical Investigator
Organisme : Fonds Wetenschappelijk Onderzoek
ID : E.D. is a postdoctoral research fellow (grant number: 12X9420N)
Références
Gastroenterology. 2018 Apr;154(5):1343-1351.e1
pubmed: 29317275
Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9
pubmed: 26681486
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1814-1821.e1
pubmed: 30613004
Gastroenterology. 2017 Sep;153(3):835-857.e6
pubmed: 28774547
J Crohns Colitis. 2021 Aug 06;:
pubmed: 34355244
Curr Opin Pharmacol. 2020 Dec;55:53-59
pubmed: 33128934
Br J Clin Pharmacol. 2019 Apr;85(4):782-795
pubmed: 30634202
AAPS J. 2018 Aug 15;20(5):91
pubmed: 30112626
Front Pharmacol. 2020 Mar 03;11:172
pubmed: 32194411
Arthritis Rheumatol. 2017 Jan;69(1):108-113
pubmed: 27894157
Br J Clin Pharmacol. 2021 Oct;87(10):3776-3789
pubmed: 33604964
Gastroenterology. 2014 Dec;147(6):1296-1307.e5
pubmed: 25173754
JAMA. 2021 May 4;325(17):1744-1754
pubmed: 33944876
Aliment Pharmacol Ther. 2016 Jan;43(1):30-51
pubmed: 26515897
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787
pubmed: 30255663
Autoimmun Rev. 2014 Jan;13(1):24-30
pubmed: 23792214
Gut. 2010 Jan;59(1):49-54
pubmed: 19651627
Br J Clin Pharmacol. 2021 Jan;87(1):106-118
pubmed: 32415677
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
J Pharmacokinet Biopharm. 1986 Oct;14(5):539-55
pubmed: 3806375
Clin Gastroenterol Hepatol. 2015 Mar;13(3):531-8
pubmed: 25117777
Gastroenterology. 2015 Jun;148(7):1320-9.e3
pubmed: 25724455
J Gastroenterol. 2016 Mar;51(3):241-51
pubmed: 26162647
Clin Gastroenterol Hepatol. 2021 Feb;19(2):288-295.e4
pubmed: 32200087
Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8.e1-2
pubmed: 26545802
Clin Gastroenterol Hepatol. 2021 Mar;19(3):511-518.e6
pubmed: 32348905
Clin Gastroenterol Hepatol. 2020 May;18(6):1291-1299
pubmed: 31589978
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053
pubmed: 29027257
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
J Crohns Colitis. 2016 Nov;10(11):1273-1278
pubmed: 27106537